The Effect of Statin Medications on Muscle Performance (The STOMP Study)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-01-31

Study Completion Date

2011-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Statins are a group of medications that are used to lower cholesterol levels. Although serious side effects are rare, some people taking statins experience muscle pain or weakness. This study will evaluate the number of people who experience mild muscle complaints and will determine the effect of statins on skeletal muscle strength, endurance, and aerobic exercise performance.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

NCT03351998

Mitochondrial Diseases

COMPLETED PHASE4

A Tool to Help Patients With Muscle Symptoms After Taking a Statin Medication.

NCT06423365

Hydroxymethylglutaryl-CoA Reductase Inhibitors Hypercholesterolemia Cardiovascular Diseases +2 more

ACTIVE_NOT_RECRUITING NA

Muscle Characteristics Associated With Statin Therapy

NCT00990834

Hydroxymethylglutaryl-CoA Reductase Inhibitors Myopathy

WITHDRAWN NA

Metabolic Features of Post-Myopathy Patients Associated With Statin Treatment

NCT01040650

Myopathy (Statin Associated)

TERMINATED

Is Myopathy Part of Statin Therapy (IMPOSTER-16)

NCT00127335

Myopathic Conditions

WITHDRAWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Statins are the most effective medications for reducing high cholesterol levels. They are extremely well tolerated by the majority of people but can produce a variety of muscle-related side effects in some people. Of these side effects, the most serious is rhabdomyolysis, which involves muscle fiber damage that can begin as muscle pain and progress to a loss of muscle cells, kidney failure, and death. While rhabdomyolysis is extremely rare, some people experience the more common muscle-related side effects of statins, such as muscle pain (known as "myalgia"), cramps, and weakness. These more common side effects warrant attention because they may limit the use of statins, affect mobility, and increase the risk of injury in older individuals. Also, the term "muscle weakness," often used by patients and their doctors, is not well defined and can refer to a wide range of complaints from simple fatigue to an actual inability to perform activities of daily living. It is important to describe and quantify in more detail the muscle-related side effects associated with statins. The purpose of this study is to determine the incidence of statin-induced mild muscle complaints and to determine the effect of statins on skeletal muscle strength, endurance, and aerobic exercise performance.

This study will enroll healthy people who have never received statin medications. First, participants will attend three study visits over a period of 2 weeks. These study visits will include blood collection, questionnaires on physical activity and pain, vital sign measurements, and body measurements, including height, weight, and head circumference. Participants will also complete two cardiopulmonary exercise stress tests on a treadmill and will undergo arm and leg strength testing. Some participants may undergo a muscle biopsy. Participants will then be randomly assigned to receive either 80 mg of atorvastatin or placebo on a daily basis for 6 months. Blood will be collected again at Month 3. At Month 6, participants will attend two study visits for repeat baseline measurements. All participants will be contacted by phone every other week during the 6-month treatment period to monitor adverse events and medication compliance.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hydroxymethylglutaryl-CoA Reductase Inhibitors Muscular Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Participants will receive atorvastatin for 6 months.

Group Type EXPERIMENTAL

Atorvastatin

Intervention Type DRUG

80-mg atorvastatin capsules taken daily for 6 months

2

Participants will receive matching placebo for 6 months.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo capsules taken daily for 6 months

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Atorvastatin

80-mg atorvastatin capsules taken daily for 6 months

Intervention Type DRUG

Placebo

Placebo capsules taken daily for 6 months

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lipitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Statin-naive (i.e., has never taken statins before)

Exclusion Criteria

* Previous use of statins
* Current treatment with cholesterol- or triglyceride-lowering drugs
* Impaired liver or kidney function
* Untreated hypothyroidism or hyperthyroidism
* Treatment with other medications known to increase risk of myopathy in atorvastatin-treated patients (e.g., cyclosporine, azithromycin, erythromycin, azole antifungals, fusidic acid)
* Existing infection requiring treatment with antibiotic therapy
* Consumption of greater that 1 quart of grapefruit juice per day
* Documented history of neuroleptic malignant syndrome
* Inherited muscle disorders or myopathy
* Known sickle cell trait
* Cancer within the 5 years prior to study entry
* Diabetes
* Currently being treated for high blood pressure
* Coronary artery disease
* Peripheral vascular disease
* Physical disability or previous injury that prevents safe exercise testing
* Pregnant or breastfeeding

Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes